Mirvaso

RSS

brimonidine

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Mirvaso. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Mirvaso.

For practical information about using Mirvaso, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 06/12/2018

Authorisation details

Product details
Name
Mirvaso
Agency product number
EMEA/H/C/002642
Active substance
brimonidine tartrate
International non-proprietary name (INN) or common name
brimonidine
Therapeutic area (MeSH)
Skin Diseases
Anatomical therapeutic chemical (ATC) code
D11AX21
Publication details
Marketing-authorisation holder
Galderma International
Revision
9
Date of issue of marketing authorisation valid throughout the European Union
20/02/2014
Contact address
Tour Europlaza
La Défense 4
20 avenue André Prothin
92927 La Défense Cedex
France

Product information

22/11/2018 Mirvaso - EMEA/H/C/002642 - R/0021

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

OTHER DERMATOLOGICAL PREPARATIONS

Therapeutic indication

Mirvaso is indicated for the symptomatic treatment of facial erythema of rosacea in adult patients.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating